Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Good bacteria lozenges aim to fight gum disease and bad breath

NCT ID NCT07508839

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 21, 2026 · Updated 2 times

Summary

This study tests whether a probiotic lozenge containing a special strain of Streptococcus salivarius (SALI-10) can reduce gum inflammation and bad breath. Sixty adults with gingivitis will take the lozenge or a placebo twice daily for four weeks. The goal is to see if the probiotic helps control gum disease and improve oral health without the need for ongoing medication.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

Apr 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Male or female volunteers aged 18-70 years 2. In good general health, ASA I 3. Non-smokers 4. Fluent in English 5. For sexually active volunteers of childbearing potential, one of the following methods must be used to prevent pregnancy during the study by participants. 1. Post-menopausal 2. hormonal birth control (oral, injectable, transdermal, intra-vaginal) or intrauterine device must be in use at least 30 days prior to first study drug administration; 3. barrier methods must be in use at least 14 days prior to study drug administration; 4. that vasectomy on the male partner must be completed 3 months prior to first study drug administration; 5. or in the alternative that a 0 sperm count for the male partner will suffice Exclusion Criteria: 1. Presence of orthodontic bands. 2. Presence of partial removal dentures. 3. Dental pain at time of screening. 4. History of allergy to a consumer or personal care products or dentifrice ingredients as determined by the dental profession monitoring the study, or to any of the following: sorbitol, isomalt, dibasic calcium phosphate, potato or potato starch, mint or mint flavour, glyceryl dibehenate, steviol glycosides. 5. Participation in any other clinical study or test panel within one month before entering the study. 6. Current use of anti-inflammatory, antibiotics, or antimicrobial drugs or within the last 30 days of enrolment. 7. Those taking anticoagulant medications and have blood and bleeding disorders 8. Those who have recently experienced (past 30 days) or will be experiencing (next 90 days) dental, oral, or any type of surgery 9. History of systemic inflammatory or immune conditions or immunocompromised conditions 10. Pregnant or nursing women or those planning on getting pregnant. 11. Use of tobacco products. 12. Long-term antibiotic or anti-inflammatory therapy. 13. Medical condition or any current usage of medication that the investigator considers may compromise the subject's safety as well as the quality of the study results (note, only Advil and Tylenol are allowed during the study for analgesia) 14. Medication or Natural Health Products (NHPs) that could affect the gingiva like calcium channel blockers, anti-epileptic therapy etc. 15. Participants who are experiencing nausea, fever, vomiting, bloody diarrhoea or severe abdominal pain. 16. Presence of active infections 17. Use of any probiotic 18. Use of anti-plaque/anti-gingivitis products 19. Subjects who must receive dental treatment during the study elates 20. Concurrent orthodontic treatment 21. Untreated carious lesions and/or inadequate restorations on maxillary posterior teeth 22. Periodontal disease (periodontal pockets, probing depth (PD) \< 3.0 mm on at least one tooth/site, presence of Clinical Attachment Loss (CAL) = 0 mm, or periodontal disease history)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gingivitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

gingivitis Halitosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    1 site. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • OMGPerio

    RECRUITING

    Hamilton, Ontario, L8N 1K4, Canada

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.